ATE400564T1 - Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen - Google Patents

Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen

Info

Publication number
ATE400564T1
ATE400564T1 AT03771907T AT03771907T ATE400564T1 AT E400564 T1 ATE400564 T1 AT E400564T1 AT 03771907 T AT03771907 T AT 03771907T AT 03771907 T AT03771907 T AT 03771907T AT E400564 T1 ATE400564 T1 AT E400564T1
Authority
AT
Austria
Prior art keywords
dyslipidemia
treatment
lipid disorders
ppar alpha
selective compounds
Prior art date
Application number
AT03771907T
Other languages
English (en)
Inventor
Guo Shi
Yong Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE400564T1 publication Critical patent/ATE400564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03771907T 2002-07-30 2003-07-25 Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen ATE400564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39952002P 2002-07-30 2002-07-30

Publications (1)

Publication Number Publication Date
ATE400564T1 true ATE400564T1 (de) 2008-07-15

Family

ID=31188592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03771907T ATE400564T1 (de) 2002-07-30 2003-07-25 Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen

Country Status (8)

Country Link
US (1) US7524882B2 (de)
EP (1) EP1539136B1 (de)
JP (1) JP4475406B2 (de)
AT (1) ATE400564T1 (de)
AU (1) AU2003256842B8 (de)
CA (1) CA2491733A1 (de)
DE (1) DE60322075D1 (de)
WO (1) WO2004010936A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256842B8 (en) 2002-07-30 2009-06-18 Merck Sharp & Dohme Corp. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
EP1630152A4 (de) 2003-05-30 2009-09-23 Takeda Pharmaceutical Verbindung mit kondensiertem ring
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
WO2005024057A1 (en) * 2003-09-10 2005-03-17 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20090036489A1 (en) * 2005-03-22 2009-02-05 Masahiro Nomura Novel Cyclic Aminophenylalkanoic Acid Derivative
EP2025674A1 (de) * 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JPWO2009087981A1 (ja) * 2008-01-11 2011-05-26 株式会社Kri 重合性化合物及びこの製造方法
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
CN104968659A (zh) 2013-02-06 2015-10-07 住友化学株式会社 稠合杂环化合物
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN108546245A (zh) * 2018-05-22 2018-09-18 绍兴文理学院 一种抗增殖活性中间体ml-098的制备方法
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205080A (en) 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
US4213999A (en) 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
US4213998A (en) 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
DE3265715D1 (en) 1981-03-24 1985-10-03 Fisons Plc Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them
JPS61158976A (ja) * 1984-12-28 1986-07-18 Shionogi & Co Ltd ベンゾフランおよびベンゾチオフエン誘導体
FR2645537B1 (fr) 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
US5273999A (en) 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5352690A (en) 1992-07-01 1994-10-04 Eli Lilly And Company 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
JP3187611B2 (ja) * 1993-05-17 2001-07-11 キヤノン株式会社 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
CA2427610A1 (en) 2000-10-31 2002-08-08 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2003256842B8 (en) 2002-07-30 2009-06-18 Merck Sharp & Dohme Corp. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Also Published As

Publication number Publication date
US7524882B2 (en) 2009-04-28
AU2003256842A1 (en) 2004-02-16
EP1539136A2 (de) 2005-06-15
WO2004010936A2 (en) 2004-02-05
AU2003256842B2 (en) 2009-02-19
EP1539136A4 (de) 2006-10-18
EP1539136B1 (de) 2008-07-09
JP2006500335A (ja) 2006-01-05
AU2003256842B8 (en) 2009-06-18
JP4475406B2 (ja) 2010-06-09
US20050228044A1 (en) 2005-10-13
WO2004010936A3 (en) 2004-08-26
CA2491733A1 (en) 2004-02-05
DE60322075D1 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
DE60322075D1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
DE60332738D1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
BR0109703A (pt) Derivados de piperazina
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
DE602004008304D1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
SE9902267D0 (sv) New compounds
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
RU2001124802A (ru) Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
ATE488236T1 (de) Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
TW200732304A (en) Piperidine derivatives
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
ATE416162T1 (de) Naphthamidderivate und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties